How to Read a Peptide Study Without Being Fooled
Most peptide claims trace back to rodent work from a single lab. Here is how to check what a study actually showed before you believe the summary.
By Reagan Bergstrom ·
Check the species first. It takes four seconds and it resolves most peptide claims before you read another word.
An enormous share of the peptide literature is rodent work. Rodent work is not worthless, but the translation rate from promising animal result to approved human drug is somewhere around one in ten across all of pharmacology, and worse in some fields. A compound with twenty positive rat studies and zero human trials has not been shown to work in humans. It has been shown to be worth testing in humans.
The five checks
Species and route. Rats, mice, dogs or humans. Intraperitoneal injection in a rat is not a route anyone uses clinically, and doses given that way do not convert to human doses by simple bodyweight scaling.
Sample size. Peptide papers routinely run eight to twelve animals per group. That is enough to detect a large effect and nowhere near enough to detect a small one or to characterise a rare harm. Small samples also produce inflated effect sizes when they do reach significance, which is why the first study of anything usually looks better than the tenth.
Control and blinding. Was there a placebo group. Were the people scoring the outcome unaware of which animal got what. Histology scored by an unblinded investigator is the softest data in the paper and it is very often the headline result.
Outcome switching. Compare what the paper measured against what it says it set out to measure. For human trials this is checkable directly: registered trials list their primary outcome in advance on ClinicalTrials.gov, and a paper whose headline result is not the registered primary outcome is telling you something.
Who wrote it. Independent replication is the whole point of the scientific method, and its absence is informative.
The single-lab problem
That last check deserves its own section, because peptide research has a specific structural weakness.
For several popular compounds, the great majority of published work originates with one research group. BPC-157 is the clearest case: the bulk of the literature comes from a single team, largely at one institution, over roughly three decades. The papers are real and peer-reviewed. They are also not independent of one another in the way a naive citation count implies.
When you see "over a hundred studies", check how many distinct groups those studies represent. A hundred papers from one lab and a hundred papers from forty labs are very different bodies of evidence, and a citation count cannot tell them apart.
Reading a citation chain to its source
The most common failure I see in forum discussion is a claim that has drifted from its source through several retellings. A vendor page cites a blog post, the blog post cites a review article, the review article cites a 2003 rat study, and the rat study reports something considerably narrower than the vendor page claims.
Follow the chain to the primary source every time. It usually takes ten minutes and it very often ends somewhere less impressive than where it started.
What "no evidence" means and does not mean
Absence of human trials is not proof that something does not work. It means nobody has checked properly, and you are the experiment. Those are different statements, and conflating them in either direction is how both the hype and the dismissal go wrong.
The honest position for most research peptides is that the mechanism is plausible, the animal data is genuinely interesting, the human data does not exist, and the manufacturing is unregulated. All four of those are true at once.
For the vocabulary used above, see What Peptides Actually Are. For the manufacturing half of the problem, see Third-Party Testing and What a COA Proves.